PT  - JOURNAL ARTICLE
ED - BMJ Publishing Group Ltd
TI  - ▾ Pergolide (celance) – a third dopamine agonist
AID  - 10.1136/dtb.29.20.79
DP  - 1991 Sep 30
TA  - Drug and Therapeutics Bulletin
PG  - 79--79
VI  - 29
IP  - 20
4099  - http://dtb.bmj.com/content/29/20/79.1.short
4100  - http://dtb.bmj.com/content/29/20/79.1.full
SO  - Drug Ther Bull1991 Sep 30; 29
AB  - Pergolide (Celance – Lilly) is structurally related to bromocriptine and lysuride. Like them it is a dopamine agonist intended for use with levodopa in Parkinson’s disease,1 but unlike other agonists pergolide stimulates D1 as well as D2 receptors. The manufacturer suggests that this ‘dual action’ allows ‘full expression of the effects of dopaminergic therapy’ and ‘may contribute to the therapeutic efficacy’, but the clinical relevance of differential dopamine receptor stimulation is not known.